Abstract
The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have